医药政策法规
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-05)
PROpel III 期关键结果:与阿比特龙单药相比,奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌中位总生存期的绝对差异增加了7.4个月
(2023-03-05)- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-05)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)
- (2023-03-04)